Novartis
Novartis’ Indian patent case delayed
August 23, 2012Sales and Marketing Glivec, MSF, Novartis, generics
Novartis’ court case against the Indian government has been put on hold until next month. The case was suppose to …
Novartis eye drug succeeds in Phase III trial
August 16, 2012Sales and Marketing FDA, Novartis, Ocriplasmin, Roche, VMA
Novartis has posted positive results for its investigational eye drug ocriplasmin. The Phase III study found that ocriplasmin significantly resolved …
MSD joins forces with PatientsLikeMe for psoriasis
August 14, 2012Medical Communications MSD, Novartis, PatientsLikeMe, digital, psoriasis
MSD has teamed up with the online patient community site ‘PatientsLikeMe’ to gauge the impact of psoriasis on patients, whilst …
New Avastin data could be bad news for Lucentis
August 14, 2012Research and Development, Sales and Marketing DMO, Lucentis, Novartis, Roche, avastin, off label, off-label, wet AMD
The day after Novartis gained a new US licence for Lucentis to treat diabetic macular oedema, new data was published …
Novartis pledges to maintain R&D presence in Horsham
August 14, 2012Manufacturing and Production, Research and Development Horsham, NIBR, Novartis, R&D, cuts
Novartis has confirmed that it intends to maintain a presence at its site in Horsham, UK, which has already seen …
Novartis and Pennsylvania team up on cancer research
August 6, 2012Research and Development Cancer, Novartis, University of Pennsylvania, chimeric antigen receptor
Novartis and the University of Pennsylvania have joined forces to investigate a method of treating cancer which encourages patients’ immune …
Novartis’ David Meek moves to Endocyte
July 30, 2012Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing David Meek, Endocyte, Novartis, appointment
David Meek has been appointed to the newly created position of chief commercial officer at the biotechnology firm Endocyte. Meek …
Ireland agrees deal on medicines
June 28, 2012Business Services, Sales and Marketing AstraZeneca, IPHA, Ireland, Lundbeck, Novartis, pricing
Ireland’s pharmaceutical industry has agreed a deal with the country’s government which breaks a deadlock over prices and access. The …
Roche cuts 1,000 R&D jobs
June 27, 2012Research and Development, Sales and Marketing AZ, Genentech, Novartis, R&D, Roche, cuts
Roche will make major cuts to its research operations in the US and revamp operations in Europe. Roche will close …
Pharma companies share $400m US biosecurity contract
June 26, 2012Manufacturing and Production Emergent BioSolutions, GSK, Novartis, manufacturing
GlaxoSmithKline, Novartis and Emergent BioSolutions will share a $400 million contract from the US government to provide vaccine manufacturing capacity …
Afinitor recommended in Europe for breast cancer
June 22, 2012Sales and Marketing Afinitor, CHMP, Cancer, Novartis, breast
A European committee is recommending Novartis’ Afinitor to treat women with a certain type of breast cancer. The CHMP says …
Packaging errors spark fourth oral contraceptive recall
June 12, 2012Manufacturing and Production Introvale, Novartis, Sandoz, manufacturing, recall
There has been yet another case of an oral contraceptive being recalled because packaging errors could lead to unwanted pregnancy, …
Merck Serono staff may strike over Geneva HQ closure
June 6, 2012Manufacturing and Production, Research and Development ASCO, Basel, Geneva, Merck Serono, Novartis, R&D
Workers at Merck Serono’s Swiss headquarters in Geneva have threatened industrial action over the company’s plans to shut down the …
Gilenya to stay on US market – but with new safety warnings
May 15, 2012Sales and Marketing EMA, FDA, Novartis, PML, gilenya
The FDA says that Novartis’ multiple sclerosis pill Gilenya should stay on the market, but has added new safety warnings …
Former Novartis man becomes GSK’s new medical director
May 8, 2012Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing GSK, James Shannon, Novartis
James Shannon has been named GSK’s chief medical officer, and will report to R&D chairman Moncef Slaoui. He will be …
Latest content
FibroFind appoints Lee Borthwick as CEO
